19:50 IST
BSE
Business Update
Piramal Pharma Business Update
Piramal Pharma reported that the US FDA issued a Form-483 with 7 observations following a GMP inspection of its Morpeth, UK facility.
Piramal Pharma Ltd
- Share price
- ₹202.67
- Market cap
- ₹26,982 Cr
- Revenue (annual)
- ₹8,869 Cr
- Net profit (annual)
- ₹-325.9 Cr
- P/E (TTM)
- -86.0×Sector 47.4×
- Promoter holding
- 34.80%-0.06% QoQ
- FII holding
- 12.51%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
2 announcements with these filters
17:01 IST
BSE
Business Update
Piramal Pharma Business Update
Piramal Pharma Limited released its Sustainability Report for FY2025-26, detailing the company's ESG performance across key pillars, including business resilience and operational sustainability.